JP7307047B2 - 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療 - Google Patents

組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療 Download PDF

Info

Publication number
JP7307047B2
JP7307047B2 JP2020500617A JP2020500617A JP7307047B2 JP 7307047 B2 JP7307047 B2 JP 7307047B2 JP 2020500617 A JP2020500617 A JP 2020500617A JP 2020500617 A JP2020500617 A JP 2020500617A JP 7307047 B2 JP7307047 B2 JP 7307047B2
Authority
JP
Japan
Prior art keywords
rvwf
vwf
infusion
hours
participants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020500617A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020526525A5 (OSRAM
JP2020526525A (ja
Inventor
ミランダ チャップマン
ブルース イーウェンスタイン
ベッティーナ プロダー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2020526525A publication Critical patent/JP2020526525A/ja
Publication of JP2020526525A5 publication Critical patent/JP2020526525A5/ja
Priority to JP2023106554A priority Critical patent/JP7641327B2/ja
Application granted granted Critical
Publication of JP7307047B2 publication Critical patent/JP7307047B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020500617A 2017-07-07 2018-07-09 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療 Active JP7307047B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023106554A JP7641327B2 (ja) 2017-07-07 2023-06-29 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762530027P 2017-07-07 2017-07-07
US62/530,027 2017-07-07
PCT/US2018/041320 WO2019010497A1 (en) 2017-07-07 2018-07-09 TREATMENT OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH A SEVERE FORM OF VON WILLEBRAND'S DISEASE BY RECOMBINANT VWF ADMINISTRATION

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023106554A Division JP7641327B2 (ja) 2017-07-07 2023-06-29 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療

Publications (3)

Publication Number Publication Date
JP2020526525A JP2020526525A (ja) 2020-08-31
JP2020526525A5 JP2020526525A5 (OSRAM) 2021-08-12
JP7307047B2 true JP7307047B2 (ja) 2023-07-11

Family

ID=63036433

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020500617A Active JP7307047B2 (ja) 2017-07-07 2018-07-09 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療
JP2023106554A Active JP7641327B2 (ja) 2017-07-07 2023-06-29 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023106554A Active JP7641327B2 (ja) 2017-07-07 2023-06-29 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療

Country Status (16)

Country Link
US (5) US10632176B2 (OSRAM)
EP (2) EP4424366A3 (OSRAM)
JP (2) JP7307047B2 (OSRAM)
KR (2) KR102921337B1 (OSRAM)
CN (1) CN111436193A (OSRAM)
AU (2) AU2018298233B2 (OSRAM)
BR (1) BR112020000321A2 (OSRAM)
CA (1) CA3069295A1 (OSRAM)
CO (1) CO2020001322A2 (OSRAM)
DK (1) DK3648788T3 (OSRAM)
ES (1) ES2986574T3 (OSRAM)
FI (1) FI3648788T5 (OSRAM)
MX (1) MX2025012580A (OSRAM)
PL (1) PL3648788T3 (OSRAM)
PT (1) PT3648788T (OSRAM)
WO (1) WO2019010497A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3648788T3 (da) 2017-07-07 2024-08-19 Takeda Pharmaceuticals Co Behandling af gastrointestinal blødning hos patienter med svær von willebrand-sygdom ved administration af rekombinant vwf
PT3648787T (pt) 2017-07-07 2025-01-20 Takeda Pharmaceuticals Co Tratamento de doentes com doença de von willebrand grave submetidos a cirurgia eletiva por administração de vwf recombinante
BR112021015068A2 (pt) 2019-02-01 2021-10-05 Takeda Pharmaceutical Company Limited Métodos de tratamento profilático usando vwf recombinante (rvwf)
US20220395560A1 (en) * 2019-02-01 2022-12-15 Takeda Pharmaceutical Company Limited METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF)
WO2021032646A1 (en) * 2019-08-16 2021-02-25 Octapharma Ag Stabilizing buffer for factor viii and vwf

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US8597910B1 (en) 1985-04-11 2013-12-03 Children's Medical Center Corporation DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells
WO1986006096A1 (en) 1985-04-11 1986-10-23 The Children's Medical Center Corporation Von willebrand factor
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
US6005077A (en) 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT406373B (de) 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT405485B (de) 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
WO2004039337A2 (en) 2002-10-31 2004-05-13 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
WO2005012354A1 (en) 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
BRPI0519562A2 (pt) 2004-12-27 2009-01-27 Baxter Int construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁcea
SI2522717T1 (sl) 2006-01-04 2014-05-30 Baxter International Inc. Mediji celične kulture brez oligopeptidov
AU2008261261B2 (en) 2007-06-13 2013-06-27 Csl Behring Gmbh Use of VWF stabilized FVIII preparations and of VWF preparations without FVIII for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
AU2008323768A1 (en) 2007-11-09 2009-05-14 Baxter Healthcare S.A. Modified recombinant Factor VIII and von Willebrand Factor and methods of use
WO2009086400A2 (en) 2007-12-28 2009-07-09 Baxter International Inc. Recombinant vwf formulations
DK2865760T3 (en) 2008-06-24 2018-01-15 Csl Behring Gmbh Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
DK2349314T3 (da) 2008-10-21 2013-05-27 Baxter Int Lyofiliserede præparater af rekombinant VWF
WO2011017414A2 (en) 2009-08-04 2011-02-10 Baxter International Inc. Transgenic mouse lacking endogenous fviii and vwf - a model of hemophilia a
PT3626736T (pt) 2010-07-08 2025-08-11 Takeda Pharmaceuticals Co Método de produção de fvw recombinante de elevado peso molecular na cultura celular
KR101969515B1 (ko) 2011-06-10 2019-04-16 박스알타 인코퍼레이티드 재조합 vwf의 투여에 의한 응고 질환의 치료
CA2978374A1 (en) 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
DK3648788T3 (da) 2017-07-07 2024-08-19 Takeda Pharmaceuticals Co Behandling af gastrointestinal blødning hos patienter med svær von willebrand-sygdom ved administration af rekombinant vwf

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Joan C Gill et al.，hemostaticefficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease，Blood，2015年，Vol. 126, No. 16，p. 2038-2046，doi: 10.1182/blood-2015-02-629873
MASSIMO FRANCHINI，GASTROINTESTINAL ANGIODYSPLASIA AND BLEEDING IN VON WILLEBRAND DISEASE，THROMBOSIS AND HAEMOSTASIS，ドイツ，2014年，VOL:112, NR:9，PAGE(S):427 - 431，http://dx.doi.org/10.1160/TH13-11-0952
PIER MANNUCCIO MANNUCCI，PHARMACOKINETICS AND SAFETY OF A NOVEL RECOMBINANT HUMAN VON WILLLEBRAND FACTOR MANUFACTURED WITH A PLASMA-FREE METHOD: A PROSPECTIVE CLINICAL TRIAL，BLOOD，2013年06月18日，VOL:122,NR:5，PAGE(S):648-657，https://ashpublications.org/blood/article/122/5/648/32057

Also Published As

Publication number Publication date
EP4424366A3 (en) 2024-12-04
KR102921337B1 (ko) 2026-02-02
CN111436193A (zh) 2020-07-21
AU2018298233A1 (en) 2020-01-30
RU2020105682A (ru) 2021-08-10
US20230122958A1 (en) 2023-04-20
ES2986574T3 (es) 2024-11-12
US10905746B2 (en) 2021-02-02
JP7641327B2 (ja) 2025-03-06
FI3648788T5 (fi) 2024-09-09
JP2023123738A (ja) 2023-09-05
KR20200037235A (ko) 2020-04-08
FI3648788T3 (fi) 2024-08-16
PL3648788T3 (pl) 2024-10-07
WO2019010497A1 (en) 2019-01-10
US11529395B2 (en) 2022-12-20
US20210169989A1 (en) 2021-06-10
EP3648788B1 (en) 2024-05-22
US20200206318A1 (en) 2020-07-02
PT3648788T (pt) 2024-08-23
US20240316160A1 (en) 2024-09-26
MX2025012580A (es) 2026-01-07
AU2018298233B2 (en) 2025-04-24
BR112020000321A2 (pt) 2020-07-14
DK3648788T3 (da) 2024-08-19
EP4424366A2 (en) 2024-09-04
AU2025205392A1 (en) 2025-09-25
CO2020001322A2 (es) 2020-02-18
JP2020526525A (ja) 2020-08-31
RU2020105682A3 (OSRAM) 2021-10-15
US12016904B2 (en) 2024-06-25
US10632176B2 (en) 2020-04-28
KR20260037107A (ko) 2026-03-17
EP3648788A1 (en) 2020-05-13
US20190091299A1 (en) 2019-03-28
CA3069295A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
JP7641327B2 (ja) 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療
CN107412743A (zh) 通过施用重组vwf治疗凝血疾病
JP2025128168A (ja) 組換えＶＷＦ（ｒＶＷＦ）を使用する予防治療法
JP2023085513A (ja) 待機手術を受ける、重度のフォンヴィレブランド病を患う患者の、組換えｖｗｆの投与による治療法
US20220395560A1 (en) METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF)
RU2774720C2 (ru) ЛЕЧЕНИЕ ЖЕЛУДОЧНО-КИШЕЧНОГО КРОВОТЕЧЕНИЯ У ПАЦИЕНТОВ С ТЯЖЕЛОЙ ФОРМОЙ БОЛЕЗНИ ФОН ВИЛЛЕБРАНДА ПУТЕМ ВВЕДЕНИЯ РЕКОМБИНАНТНОГО ФфВ
US20230398188A1 (en) Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf
HK40115617A (en) Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
EA047451B1 (ru) СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)
HK40029176B (en) Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
HK40029176A (en) Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
HK40031159A (en) Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200310

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210629

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210629

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230329

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230531

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230629

R150 Certificate of patent or registration of utility model

Ref document number: 7307047

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150